دوره 15، شماره 4 - ( 6-1403 )
جلد 15 شماره 4 صفحات 712-706 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Alizadeh Sadighi S, Rostami N, Tohidi M, Mashayekhi M. Insulin-like growth factor (IGF) levels in pre-treatment plasma identifying breast cancer: A case control study. Caspian J Intern Med 2024; 15 (4) :706-712
URL: http://caspjim.com/article-1-3960-fa.html
URL: http://caspjim.com/article-1-3960-fa.html
Insulin-like growth factor (IGF) levels in pre-treatment plasma identifying breast cancer: A case control study. . 1403; 15 (4) :706-712
چکیده: (406 مشاهده)
Background: Diabetes (primarily type 2) is linked to a higher risk of breast cancer. Insulin-like growth factor (IGF) is one of the most important factors that affects mitosis and thus inhibits apoptosis. The purpose of this study was to compare the pre-treatment insulin-like growth factor (IGF) levels in breast cancer against normal population.
Methods: In this case-control study, 60 patients with breast cancer and 60 healthy controls were enrolled in 2017 and 2018 at Tehran's Shahid-Modarres Hospital. In this study, the blood sugar of the patients was examined before entering the study, and the age of the patients was also within the age limit of 18 to 70 years. They were studied to determine the relationship between insulin-like growth factor (ELISA method) and breast cancer.
Results: Both groups have similar IGF-1 levels (Ctrl and Case) (P= 0.188). But, IGF-2 levels were significantly higher in breast cancer patients (373.4 vs. 317.3 ng/ml), (P=0.0001).
Conclusion: According to our study, IGF-2 may serve as a prognostic biomarker and potential therapeutic target for breast cancer. However, further investigation is needed to validate this claim.
Methods: In this case-control study, 60 patients with breast cancer and 60 healthy controls were enrolled in 2017 and 2018 at Tehran's Shahid-Modarres Hospital. In this study, the blood sugar of the patients was examined before entering the study, and the age of the patients was also within the age limit of 18 to 70 years. They were studied to determine the relationship between insulin-like growth factor (ELISA method) and breast cancer.
Results: Both groups have similar IGF-1 levels (Ctrl and Case) (P= 0.188). But, IGF-2 levels were significantly higher in breast cancer patients (373.4 vs. 317.3 ng/ml), (P=0.0001).
Conclusion: According to our study, IGF-2 may serve as a prognostic biomarker and potential therapeutic target for breast cancer. However, further investigation is needed to validate this claim.
نوع مطالعه: Short Communication |
موضوع مقاله:
Oncology
دریافت: 1402/2/27 | پذیرش: 1402/9/14 | انتشار: 1403/5/18
دریافت: 1402/2/27 | پذیرش: 1402/9/14 | انتشار: 1403/5/18
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
